Evidence map›Paper›PMID 41273773›Full record

ArticleProtein & cell2026

Multidimensional single-cell analysis reveals immune dysfunction and inflammatory response in lymphatic malformations.

Chunxiao Chen, Wenhao Ju, Xueying Li, Kexin Yao, Jun Cao, Songqi Duan, Xueqi Lv, Tianli Zhang, Sanlin Li, Jiawen Li and 3 more

Abstract read
In one paragraph

Article in Protein & cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Chunxiao ChenVascular Anomalies and Vascular Interventional Center, Capital Center for Children's Health, Capital Medical University, Capital Institute of Pediatrics, Beijing 100020, China.ORCID 0009-0007-8463-9301
Wenhao JuState Key Laboratory of Cardiovascular Disease, Department of Structural Heart Disease, National Center for Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Key Laboratory of Innovative Cardiovascular Devices, Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.ORCID 0000-0003-4361-0522
Xueying LiState Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Responses, College of Life Sciences, Nankai University, Tianjin 300071, China.ORCID 0000-0002-1471-7948
Kexin YaoState Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Responses, College of Life Sciences, Nankai University, Tianjin 300071, China.ORCID 0009-0002-9503-8003
Jun CaoCollege of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, China.ORCID 0000-0003-0211-9227
Songqi DuanCollege of Food Science, Sichuan Agricultural University, Ya'an 625014, China.ORCID 0000-0002-0822-5883
Xueqi LvState Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Responses, College of Life Sciences, Nankai University, Tianjin 300071, China.ORCID 0000-0003-1739-5806
Tianli ZhangState Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Responses, College of Life Sciences, Nankai University, Tianjin 300071, China.ORCID 0009-0001-9593-6535
Sanlin LiVascular Anomalies and Vascular Interventional Center, Capital Center for Children's Health, Capital Medical University, Capital Institute of Pediatrics, Beijing 100020, China.ORCID 0009-0004-7842-9146
Jiawen LiVascular Anomalies and Vascular Interventional Center, Capital Center for Children's Health, Capital Medical University, Capital Institute of Pediatrics, Beijing 100020, China.ORCID 0009-0002-3397-2888
Feng HeDepartment of Biochemistry and Immunology, Capital Center for Children's Health, Capital Medical University, Capital Institute of Pediatrics, Beijing 100020, China.ORCID 0000-0001-5692-5561
Baofa SunState Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Responses, College of Life Sciences, Nankai University, Tianjin 300071, China.ORCID 0000-0002-8221-1279
Gang ShenVascular Anomalies and Vascular Interventional Center, Capital Center for Children's Health, Capital Medical University, Capital Institute of Pediatrics, Beijing 100020, China.ORCID 0000-0002-3318-215X

Funding

Fundamental Research Funds for the Central UniversitiesNankai University 63223026Nankai University 63233045Nankai University 63241536National Natural Science Foundation of China 32170497National Natural Science Foundation of China 32261160571Special Research Fund for Central Universities, Peking Union Medical College 3332023020Tianjin Natural Science Foundation 22JCZXJC00090Tianjin Science and Technology Major Project 24ZXZSSS00490
6 · The paper itself

Abstract

Lymphatic malformations (LMs) are debilitating and potentially life-threatening diseases. However, the immune phenotype of circulating cells and underlying molecular mechanisms in LMs remain poorly understood. Here, we performed integrated single-cell RNA, T-cell receptor, and B-cell receptor sequencing (scRNA-seq, scTCR-seq, and scBCR-seq) of peripheral blood and pleural effusion from patients with LMs to delineate their immune landscape. We identified an expansion of pro-inflammatory CD14+CD16+ monocytes and atypical memory B cells, accompanied by reduced cytotoxic CD8+ T and natural killer (NK) cells. Functional analysis revealed impaired antigen processing and presentation in CD14+ monocytes, and dysregulated transcription factor activity, potentially driving immune dysfunction. Additionally, LMs exhibited substantial remodeling of TCR and BCR repertoires, with shifts in clonality and diversity. Moreover, the CXCL16-CXCR6 interaction was associated with inflammatory responses, while upregulation of the inhibitory checkpoint HLA-E: CD94-NKG2A potentially contributed to impaired NK cell activity. Finally, we constructed a shared pro-inflammatory monocyte program and revealed S100A8 as a potential therapeutic target for LMs. We further demonstrated that S100A8 pharmacological inhibition could ameliorate the pathological phenotype of LMs. Collectively, our findings delineate cell type-specific immune dysregulation in LMs, offering insights for therapeutic development.

Indexed as

InflammationLymphatic AbnormalitiesSingle-Cell AnalysisB-LymphocytesFemaleHumansKiller Cells, NaturalMaleMonocytesimmune dysfunctioninflammatory responselymphatic malformationssingle-cell RNA sequencing

Identifiers

PMID41273773
PMCPMC13107555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.